Biography

Elizabeth is a first-year associate in Sullivan's New York office. Elizabeth earned her J.D. at Suffolk University Law School, where she served as a Note Editor on the Suffolk University Law Review and as Chief of Operations to the Student Bar Association, as well as an admissions ambassador. During law school, she published a Note in the Suffolk University Law Review titled “Free the Books: A Review of Public School Students’ First Amendment Rights in the Wake of Book Removals from School Libraries.” Elizabeth received her B.A. in Politics with a minor in Philosophy from Saint Anselm College, where she was a member of the Kevin B. Harrington Student Ambassador Program to the New Hampshire Institute of Politics.

Before joining the firm, Elizabeth gained experience at various Boston law firms where she worked on commercial and employment litigation matters.

Education

Suffolk University Law School (J.D.)
Saint Anselm College (B.A.)

Bar & Court Admissions

New York

Viewpoints

All Viewpoints

New York's Medical Aid in Dying Act: Eligibility, Requirements and Planning Considerations

On August 5, 2026, Article 28-F of the New York Public Health Law (the “Medical Aid in Dying Act” or the “Act”) became effective, creating a framework under which, in certain limited circumstances, terminally ill New York residents may request and self-administer medication intended to hasten death.[i] Although narrow in its scope, the Medical Aid in Dying Act serves as a reminder of the importance of advanced healthcare planning and clearly communicating end-of-life preferences to your healthcare agent. Overview of the Medical Aid in Dying Act To qualify for medical aid in dying under the Act, an individual must: be at least 18 years old; be a resident of New York (have a New York address that is their place of abode)[ii]; have a terminal illness or condition expected to result in death within six months, as determined by the individual’s attending physician, and confirmed by a consulting physician; possess decision-making capacity, as confirmed by the attending physician, consulting physician and a mental health professional; and be physically capable of self-administering the prescribed medication.[iii] Importantly, the Act requires the individual to personally request and pursue the process. Family members, healthcare agents, agents acting under powers of attorney and other representatives may not request medication on behalf of another person.[iv] Procedural Requirements The Act establishes a multi-step process for requesting medical aid in dying. First, an individual seeking medication under the Act must make an oral and written request to the attending physician who is primarily responsible for the individual’s care. The written request must be signed and dated by the individual and witnessed by two adults.[v] Relatives, persons who may benefit financially from the individual’s death and agents acting under a healthcare proxy or power of attorney are prohibited from serving as a witness.[vi] The request must be directly submitted to the individual’s attending physician.[vii]The oral request must be recorded by audio or video and provided to the attending physician. It must then be stored in the individual’s medical records. Upon receipt of the request, the physician must discuss the individual's diagnosis and prognosis, the nature of the medication to be prescribed, the potential risks associated with its use, and feasible alternatives, including palliative or hospice care, with the individual. A mental health evaluation is also required to confirm that the individual possesses the requisite decision-making capacity.[viii] Following the required evaluations and approvals, the Act imposes a five-day waiting period before medication may be dispensed. An individual may rescind a request at any point.[ix] The Act does not require physicians to participate in providing medical aid in dying, and a physician may decline to participate. End-of-Life Planning Considerations The Medical Aid in Dying Act introduces a new end-of-life option for certain terminally ill New Yorkers while incorporating procedural safeguards intended to ensure that decisions are made voluntarily and with informed consent.[x] Although the Act is limited in its application, its enactment highlights broader planning considerations. Individuals may wish to review their existing healthcare and estate planning documents to ensure that they reflect their current wishes and to communicate those preferences to family members, healthcare providers, agents acting under healthcare directives or powers of attorney and other trusted advisors. For More Information If you would like additional information regarding the Medical Aid in Dying Act, its eligibility requirements, the procedural safeguards established by the statute or the planning considerations it may present for you or your family, please contact the Sullivan & Worcester LLP attorney with whom you regularly work or any of the attorneys listed below. This Client Alert has been prepared by Carole M. Bass, Esq., a Partner, Molly E. Depew, an Associate, and Elizabeth Johnson, an Associate, in the Private Client practice group of the international law firm of Sullivan & Worcester LLP. For more information, Ms. Bass may be reached in our New York Office by calling +1 (212) 660-4047 or by email at cbass@sullivanlaw.com; Ms. Depew may be reached at our New York Office by calling +1 (212) 660-3091 or by email at mdepew@sullivanlaw.com; and Ms. Johnson may be reached in our New York office by calling +1 (212) 660-3006 or by email at ejohnson@sullivanlaw.com. This Client Alert is provided for general informational purposes only and does not constitute legal advice. [i] N.Y. Pub. Health Law art. 28-F; 2025 N.Y. Laws ch. 714, as amended by 2026 N.Y. Laws ch. 1. [ii] New York State Department of Health, Medical Aid in Dying Law Frequently Asked Questions ("The Medical Aid in Dying law does not define the term 'resident.' The patient must have a New York State address that is the address of the patient's place of abode, not merely a mailing address. The patient must live in New York State. Patients are required to attest to their New York State residency."). [iii] N.Y. Pub. Health Law §§ 2899-d(3) (defining “decision-making capacity”), 2899-d(9) (defining “medically confirmed”), 2899-d(17) (defining “terminal illness or condition”), 2899-e(2)(a) (requiring that the attending physician determine that the individual has a terminal illness or condition and that such determination be medically confirmed by a consulting physician), 2899-h (setting forth the consulting physician's responsibilities with respect to confirmation of the individual's diagnosis, decision-making capacity, and informed decision), and 2899-i (requiring evaluation by a mental health professional to determine whether the individual has decision-making capacity to make an informed decision). [iv] N.Y. Pub. Health Law §§ 2899-d, 2899-e; New York State Department of Health, Medical Aid in Dying Law Frequently Asked Questions (explaining that a request must come directly from the patient and may not be made by an agent or surrogate). [v] § 2899-e(3). [vi] Id. §§ 2899-e, 2899-k. [vii] N.Y. Pub. Health Law §§ 2899-d(2), 2899-e(1). [viii] Id. §§ 2899-f, 2899-i. [ix] N.Y. Pub. Health Law §§ 2899-f, 2899-g. [x] See generally N.Y. Pub. Health Law art. 28-F.

SEC Stays Approval of Nasdaq’s $5 Million MVLS Continued Listing Requirement Pending Commission Review

On July 29, 2026, the Securities and Exchange Commission (the "SEC") notified Nasdaq that it had received notices of intention to petition for review of the SEC's July 22, 2026 order approving Nasdaq's proposed rule change requiring listed companies to maintain a minimum Market Value of Listed Securities ("MVLS") of $5 million. Pursuant to Rule 431(e) of the SEC's Rules of Practice, the July 22, 2026 approval order has been stayed pending further review. As discussed in our July 23, 2026 client alert, the approved rule established a new continued listing standard applicable to companies listed on the Nasdaq Capital Market, Nasdaq Global Market and Nasdaq Global Select Market. Under the approved rule, issuers that failed to maintain an MVLS of at least $5 million for 30 consecutive business days would become subject to immediate delisting procedures without the benefit of a traditional cure period. The Effect of the Stay The SEC's July 29, 2026 letter does not reverse or vacate the July 22, 2026 approval of the rule. Rather, it temporarily suspends the effectiveness of that order. According to the SEC, the stay will remain in effect "until the Commission orders otherwise." As a result, the implementation of Nasdaq's new $5 million MVLS continued listing requirement is currently on hold. Until the SEC takes further action, market participants should monitor developments regarding the review process and any subsequent order. Practical Considerations for Nasdaq Issuers Despite the stay, Nasdaq-listed companies that may be affected by the proposed MVLS requirement should continue to evaluate their compliance position and consider the potential impact of the rule should it ultimately become effective. In particular, issuers that may be at risk of falling below the proposed $5 million MVLS requirement should closely monitor whether, if the stay is lifted, any period following the July 22, 2026 approval order will count toward the rule's 30 consecutive business day requirement. We will continue to monitor developments and provide updates as additional information becomes available. For More Information If you would like additional information regarding the SEC's stay of Nasdaq's proposed $5 million MVLS continued listing requirement, the ongoing review process, Nasdaq listing standards generally, or the implications of these developments for your company, please contact the Sullivan & Worcester lawyer with whom you regularly work or any of the attorneys listed below. David Danovitch, Partner (New York) | +1 (212) 660-3060 | ddanovitch@sullivanlaw.com Oded Har-Even, Partner (New York and Tel-Aviv) | +1 (212) 660-3063 | ohareven@sullivanlaw.com Howard Berkenblit, Partner (Boston) | +1 (617) 338-2979 | hberkenblit@sullivanlaw.com Angela Gomes, Partner (Boston) | +1 (617) 338-2957 | agomes@sullivanlaw.com Joseph Segilia, Partner (New York) | +1 (212) 660-3027 | jsegilia@sullivanlaw.com Ron Ben-Bassat, Partner (New York) | +1 (212) 660-5003 | rbenbassat@sullivanlaw.com Eric Victorson, Partner (New York) | +1 (212) 660-3092 | evictorson@sullivanlaw.com Brendan O'Brien, Partner (New York) | +1 (212) 660-3013 | bobrien@sullivanlaw.com Phillip Carnevale, Associate (New York) | +1 (212) 660-3002 | pcarnevale@sullivanlaw.com Elizabeth Johnson, Associate (New York) | +1 (212) 660-3006 | ejohnson@sullivanlaw.com This Client Alert is provided for general informational purposes only and does not constitute legal advice.

News

All News

Sullivan & Worcester Welcomes 2025 First-Year Associates

Sullivan has welcomed its 2025 First-Year Associates to the firm. The five associates join Sullivan after having completed the firm’s summer associate program, in addition to various internships and clerkships. Caroline Manning, Shannon Marini and Marion Sellier will be based in Sullivan’s Boston office, while Elizabeth Johnson and Karly Roux will be based in the firm’s New York office. Elizabeth Johnson Elizabeth received her J.D., cum laude, from Suffolk University Law School, where she was Note Editor of the Suffolk University Law Review. She also served as Chief of Operations to the Student Bar Association while in law school. Elizabeth graduated cum laude from Saint Anselm College with a B.A. in politics. Caroline Manning Caroline earned her J.D., with honors, from Columbia Law School, where she was involved in the Columbia Business & Law Association and the Columbia Law Women’s Association. She received her B.S. in industrial and labor relations from Cornell University. Shannon Marini Shannon received her J.D., summa cum laude, from Suffolk University Law School, where she was Note Editor and Staff Member on the Suffolk University Law Review. While in law school, she served as a Mentor in the Women’s Law Association. Shannon received her B.S., summa cum laude, in psychological studies from the University of Pittsburgh. Karly Roux Karly earned her J.D. from the University of Southern California Gould School of Law, where she served as Alumni Relations Chair of the Women’s Law Association and the Entertainment Law Society. Karly received her B.S., summa cum laude, from the S.I. Newhouse School of Communications at Syracuse University and graduated with the Innovator Award for her senior capstone project. Marion Sellier Marion received her J.D. from Boston University School of Law, where she served as 1L Section Representative of the Asian Pacific American Law Students Association. She graduated from Brown University with an M.A. in public affairs and a B.A. in political science.

Elizabeth Johnson

Elizabeth Johnson

Biography

Elizabeth Johnson

Sullivan & Worcester Welcomes 2025 First-Year Associates

Elizabeth Johnson

New York's Medical Aid in Dying Act: Eligibility, Requirements and Planning Considerations

SEC Stays Approval of Nasdaq’s $5 Million MVLS Continued Listing Requirement Pending Commission Review

SEC Proposes Reforms to Registered Offering Framework

World Cup Marketing Without the Whistle: A Practical Guide for Non-Sponsor Brands

Featured

Stay Connected

Careers